Tolvaptan: the evidence for its therapeutic value in acute heart failure syndrome [0.03%]
托伐普坦治疗急性心力衰竭综合征的证据及其疗效价值
Arash Aghel,W H Wilson Tang
Arash Aghel
Introduction: Acute heart failure syndrome (AHFS) is one of the leading causes of hospital admission in the US. Tolvaptan is a vasopressin V(2) receptor antagonist that blocks the effect of arginine vasopressin (AVP) in r...
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus [0.03%]
维他列普汀：其在2型糖尿病治疗中的地位的证据分析
Louise Profit,Paul Chrisp,Carole Nadin
Louise Profit
Introduction: Type 2 diabetes is increasing in prevalence worldwide and is a leading cause of morbidity and mortality, mainly due to the development of complications. Vildagliptin is an inhibitor of dipeptidyl peptidase 4...
Guillaume Marquis-Gravel,Jean-Claude Tardif
Guillaume Marquis-Gravel
Introduction: Stable angina pectoris (SAP) is a widely prevalent disease affecting 30 000 to 40 000 per million people in Europe and the US. SAP is associated with reductions in quality of life and ability to work, and in...
Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation [0.03%]
甲萘雷诺酮在阿片类药物引起便秘管理中的应用证据
Peter Deibert,Carola Xander,Hubert E Blum et al.
Peter Deibert et al.
Introduction: Constipation is a distressing side effect of opioid treatment, being so irksome in some cases that patients would rather suffer the pain than the side effect of opioid analgesics. Stool softeners or stimulat...
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy [0.03%]
来那度胺在多发性骨髓瘤中的应用：基于证据的对药物治疗作用的评述
Paul Richardson,Constantine Mitsiades,Jacob Laubach et al.
Paul Richardson et al.
Introduction: Multiple myeloma (MM) is a relatively common and incurable hematological malignancy. Currently, there is no single standard therapy, with choice of treatment dependent on individual patient factors. Lenalido...
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review [0.03%]
尼洛替尼治疗慢性髓性白血病的疗效及安全性：循证评价
Elias Jabbour,Jorge Cortes,Hagop Kantarjian
Elias Jabbour
Introduction: Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional C...
Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis [0.03%]
重组人角质细胞生长因子对口腔黏膜炎的疗效研究
Stephen T Sonis
Stephen T Sonis
Purpose: Oral mucositis is a significant toxicity of cytotoxic chemo- and radiation-therapy used to treat cancer. Palifermin is the first pharmaceutical/biological agent approved for the intervention of oral mucositis. Th...
Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma [0.03%]
三阴性乳腺癌新药：临床研究与未来展望
Katherine A Thornton
Katherine A Thornton
Introduction: Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its diversity and rarity, developing ...
Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis [0.03%]
托珠单抗：其在儿童关节炎治疗中地位的证据分析
Troels Herlin
Troels Herlin
Introduction: Juvenile idiopathic arthritis (JIA) is one of the most common chronic diseases with childhood onset. It comprises different subtypes of which the systemic onset subtype is often resistant to treatment. With ...
Agomelatine: The evidence for its place in the treatment of depression [0.03%]
阿戈美拉汀：用于治疗抑郁症的证据及其地位分析
Daniela Eser,Thomas C Baghai,Hans-Jürgen Möller
Daniela Eser
Introduction: Depressive disorders are among the main causes of disability due to disease. In spite of recent progress in the pharmacotherapy of depression, there is still a high nonresponse rate of approximately 30% to t...